Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 2/20 | 0.62 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimantadine SCHEMBL15532385 | 0.77 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Rimantadine SCHEMBL2981 | 0.77 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Rimantadine SCHEMBL2982 | 0.77 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Rimantadine SCHEMBL20409367 | 0.77 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL8344710 | 0.77 | SLC22A2 (0.56) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Rimantadine SCHEMBL40906 | 0.75 | MAPT (1.00) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Rimantadine SCHEMBL4366035 | 0.75 | MAPT (1.00) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Rimantadine SCHEMBL28108817 | 0.75 | MAPT (1.00) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| SCHEMBL25492074 | 0.73 | MAPT (0.57) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B | |
| Rimantadine SCHEMBL14973619 | 0.73 | SLC22A2 (0.90) | SLC22A2SLC47A1MAPTGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420768-B2 | Polymerizable higher diamondoid derivatives | CHEVRON U.S.A. INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8013078-B2 | Heterodiamondoids | CHEVRON U.S.A. INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7981975-B2 | Heterodiamondoids | CHEVRON U.S.A. INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110112258-A1 | Polymerizable Higher Diamondoid Derivatives | CHEVRON U.S.A. INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7884256-B2 | Addition/condensation polymerization | CHEVRON U.S.A. INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7795468-B2 | Functionalized higher diamondoids | CHEVRON U.S.A. INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100190985-A1 | Heterodiamondoids | CHEVRON U.S.A. INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100094012-A1 | Heterodiamondoids | CHEVRON U.S.A. INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7649056-B2 | Triamantane diamondoid nucleus | CHEVRON U.S.A. INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1997816-A1 | Heterodiamondoids | Chevron U.S.A. Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20060183870-A1 | Heterodiamondoids | CHEVRON U.S.A. INC. | 2006-08-17 | — | — | US | disclosed |
| US-7049374-B2 | Heterodiamondoids | CHEVRON U.S.A. INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20050159634-A1 | Polymerizable higher diamondoid derivatives | CHEVRON U.S.A. INC. (US) | 2005-07-21 | — | — | US | disclosed |
| US-6858700-B2 | Polymerizable higher diamondoid derivatives | CHERVON U.S.A. INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040059145-A1 | Heterodiamondoids | CHEVRON USA INC. | 2004-03-25 | — | — | US | disclosed |
| US-20030199710-A1 | Functionalized higher diamondoids | CHEVRON U.S.A. INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1351905-A2 | POLYMERIZABLE HIGHER DIAMONDOID DERIVATIVES | Chevron USA, Inc. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20020177743-A1 | Polymerizable higher diamondoid derivatives | CHEVRON U.S.A., INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002057201-A2 | POLYMERIZABLE HIGHER DIAMONDOID DERIVATIVES | CHEVRON U.S.A. INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-3832332-A | FILMS, FIBERS | SUN RESEARCH DEVELOPMENT | 1974-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199710-A1 | Functionalized higher diamondoids | DRD3, DRD4, FANCD2 | SLC22A2 4525/4885SLC47A1 4647/4885MAPT 4442/4885 |
| US-20050159634-A1 | Polymerizable higher diamondoid derivatives | PCBP1, XRCC5, DCLRE1A | SLC22A2 4530/4885SLC47A1 4842/4885MAPT 2404/4885 |
| US-20100190985-A1 | Heterodiamondoids | WEE2, WEE1, NPM1 | SLC22A2 2105/4885SLC47A1 4142/4885MAPT 2596/4885 |
| US-20020177743-A1 | Polymerizable higher diamondoid derivatives | PCBP1, XRCC5, DCLRE1A | SLC22A2 4530/4885SLC47A1 4842/4885MAPT 2404/4885 |
| US-20040059145-A1 | Heterodiamondoids | NPM1, NDC1, WEE2 | SLC22A2 2402/4885SLC47A1 4422/4885MAPT 2408/4885 |
| US-20100094012-A1 | Heterodiamondoids | WEE2, WEE1, NPM1 | SLC22A2 2105/4885SLC47A1 4142/4885MAPT 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.